Established in 2012 by well experienced scientists, CG Biotechnologie Pharma has focused on new biological drugs and biosimilar product development meeting world standards.

Our company has developed proprietary manufacturing procedures and reliable analytical methods for providing high quality biosimilar and new biological entities for the treatment of a wide variety of diseases, immune disorders, cancers, and infections.

The development of biopharmaceutical drugs has entered a rapid growth phase stimulated by the increased market demand. To meet the increasing demand more than 300 biological drugs including monoclonal antibodies were developed, approved, and licensed by the FDA for clinical use and many more are in clinical trials. Several biologics are approved for marketing in regions other than the EU or US. We see this dynamic market situation always as challenge to expand our activities in cell culture, production, and analytics.